Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy

Br J Haematol. 2021 Sep;194(5):857-861. doi: 10.1111/bjh.17441. Epub 2021 Jul 29.

Authors

Wei Yee Chan^{1

2}, Emilie Sanchez³, Selina J Chavda^{1

2}, Catherine S Y Lecat^{1

2}, Louise Ainley^{1

2}, Ke Xu¹, Brendan Wisniowski¹, Shameem Mahmood¹, Xenofon Papanikolaou¹, Charalampia Kyriakou¹, Jonathan Sive¹, Ashutosh Wechalekar¹, Rakesh Popat¹, Neil Rabin¹, Lydia Lee^{1

2}, Eleni Nastouli³, Kwee L Yong^{1

2}

Affiliations

¹ Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
² Research Department of Haematology, UCL Cancer Institute, London, UK.
³ Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UK.

No abstract available

Keywords: COVID-19 disease; SARS-CoV-2; antibody response; multiple myeloma; plasma cell disorders.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Antibody Formation
COVID-19 / complications*
COVID-19 / diagnosis
COVID-19 / immunology
COVID-19 / therapy
COVID-19 Testing
COVID-19 Vaccines / therapeutic use
Female
Humans
Immunomodulation
Male
Middle Aged
Multiple Myeloma / complications*
Multiple Myeloma / immunology
Multiple Myeloma / therapy
SARS-CoV-2 / immunology
SARS-CoV-2 / isolation & purification

Substances

COVID-19 Vaccines

Grants and funding